Last week, a federal appeals court in Maryland ruled that a law, passed in 2017 and aimed at combatting increases in the price of generic medicines, is unconstitutional.
Last week, a federal appeals court in Maryland ruled that a law, passed in 2017 and aimed at combatting increases in the price of generic medicines, is unconstitutional.
The Association for Accessible Medicines (AAM) filed a suit against the state in a US district court in Maryland last year, alleging that the bill grants the state “unprecedented powers to regulate the national pharmaceutical market, violating the [US] Constitution and posing harm to vulnerable patient communities.”
The bill targeted “price gouging” in the sale of off-patent or generic drugs by requiring the Maryland Medical Assistance Program to notify the state’s attorney general of an increase in the prices of such medicines. In addition, it authorized the attorney general to require a drug manufacturer to turn over its records concerning the drug, and permitted a circuit court to compel action or impose penalties of up to $10,000 per infraction on the drug manufacturer.
In a 2 to 1 ruling, the 4th Circuit Court of Appeals found that the law would regulate trade beyond Maryland’s borders, which violates the so-called dormant commerce clause. Judge Stephanie D. Thacker wrote an opinion that ordered a lower-level federal judge to bar the law from taking effect.
“Maryland cannot, even in an effort to protect its consumers from skyrocketing prescription drug costs, impose its preferences in this manner,” wrote Judge Thacker.
This ruling comes as a disappointment for Maryland Attorney General Brian Frosh, who supported the bill and helped get it passed in the General Assembly in 2017.
“We remain committed to pursuing efforts to eliminate price gouging and to safeguarding Marylanders’ access to prescription drugs,” Frosh told The Baltimore Sun.
The president of the AAM, Chip Davis Jr., JD, was pleased with the outcome, saying in a statement that, “As AAM has always maintained, this law, and any others modeled from it, would harm patients because the law would reduce generic drug competition and choice, thus resulting in an overall increase in drug costs due to increased reliance upon more costly branded medications."
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.